Current Issue


Updated ADA standards of diabetes care include focus on cardiovascular issues

The American Diabetes Association (ADA) recommends assessment of 10-year atherosclerotic cardiovascular disease (ASCVD) risk in patients with diabetes and discusses appropriate use of the ASCVD calculator.

Cardiovascular event rates similar among newer second-line medications for type 2 diabetes

The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.

Drug-eluting stents may not confer advantage in diabetic patients

An editorial noted that drug-eluting stents may work for noncomplex lesions in patients with diabetes, but complex disease states incurred high rates of myocardial infarction and revascularization.

MKSAP quiz: Diabetes and elevated liver chemistry tests

This month's quiz asks readers to evaluate a 48-year-old woman with type 2 diabetes who has recently had elevated liver chemistry test results.

Spotlight on diabetes and memory

One recent study found that many patients with diabetes frequently forget to take their medications, while another analyzed the association between diabetes and brain volume and cognitive performance among older people.

In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years

The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.

Canagliflozin may not increase fracture risk in patients at low risk for fractures

Although canagliflozin has been linked to decreased bone mineral density, patients with type 2 diabetes who initiated the drug had similar risk of a first fracture as those who started a glucagon-like peptide-1 receptor agonist.